On November 25, 2024, Conduit Pharmaceuticals issued a $5.74M convertible promissory note to A.G.P./Alliance Global Partners, accruing 5.5% interest annually, due by November 25, 2025. The note allows conversion into common stock at $0.10 per share, subject to conditions including stockholder approval and authorized shares.Additionally, a Second Amendment to the Nirland Note was executed on November 22, 2024, modifying conversion terms and imposing a $100,000 daily penalty if stockholder approval is not obtained by January 9, 2025. The amendment adjusts the conversion rate to 2.5 times the principal and interest, with conditions similar to the A.G.P. note.Both notes were issued under Section 4(a)(2) exemption from registration, with potential issuance of up to 75M and 58M shares, respectively, if converted.

On November 25, 2024, Conduit Pharmaceuticals issued a $5.74M convertible promissory note to A.G.P./Alliance Global Partners, accruing 5.5% interest annually, due by November 25, 2025. The note allows conversion into common stock at $0.10 per share, subject to conditions including stockholder approval and authorized shares.Additionally, a Second Amendment to the Nirland Note was executed on November 22, 2024, modifying conversion terms and imposing a $100,000 daily penalty if stockholder approval is not obtained by January 9, 2025. The amendment adjusts the conversion rate to 2.5 times the principal and interest, with conditions similar to the A.G.P. note.Both notes were issued under Section 4(a)(2) exemption from registration, with potential issuance of up to 75M and 58M shares, respectively, if converted.